Stock REPC.F REPLICEL LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News RepliCel Life Sciences Inc.

Equities

REPC.F

CA76027P4006

Market Closed - OTC Markets
Other stock markets
 11:20:42 2024-03-15 am EDT 		5-day change 1st Jan Change
0.0428 USD +4.99% Intraday chart for RepliCel Life Sciences Inc. -.--% -4.89%
Apr. 18 RepliCel Life Sciences Inc. Announces Secured Loan Agreement CI
2023 RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RepliCel Life Sciences : Announces Secured Loan Agreement
PU
RepliCel Life Sciences Inc. Announces Secured Loan Agreement
CI
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K
PU
RepliCel Life Sciences : Letter of Intention (Asset Purchase)
PU
Canadian Investment Regulatory Organization Trading Halt - RP
AQ
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
RepliCel Life Sciences : Arbitration decision
PU
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials
PU
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director
CI
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K
PU
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors
CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes
CI
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K
PU
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K
PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REPC.F Stock
  4. News RepliCel Life Sciences Inc.